Biomarin Pharmaceutical Inc. share price logo

Biomarin Pharmaceutical Inc. Share Price

NASDAQ: BMRN

Large Cap

$57.43

-1.08

(-1.85%)

as on

Biomarin Pharmaceutical Inc. Stock Performance

as on March 17, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $56.00
    $58.80
    downward going graph

    2.49%

    Downside

    2.39%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $50.76
    $73.18
    downward going graph

    11.61%

    Downside

    27.42%

    Upside

    downward going graph

Biomarin Pharmaceutical Inc. share price movements today

Previous Close
$58.51
Open
$56.18
Volume
2.0M
Day's Low - High
$56.00 - $58.80
52 Week Low - High
$50.76 - $73.18

Biomarin Pharmaceutical Inc. Historical Returns

1 Month Return
-2.27 %
3 Month Return
+ 13.02 %
1 Year Return
-15.74 %
3 Year Return
-37.36 %
5 Year Return
-24.22 %

Biomarin Pharmaceutical Inc. Stock Fundamentals & Key Indicators

Check Biomarin Pharmaceutical Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$11.3B

EPS (TTM)

5.34

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

1.24%

PE Ratio (TTM)

32.51

Industry PE ratio

17.7675641025641

PEG Ratio

0.6808

EBITDA

722.9M

Revenue (TTM)

3.2B

Profit Margin

10.83%

Return On Equity TTM

5.94%

Biomarin Pharmaceutical Inc. Stock Valuation

Track how Biomarin Pharmaceutical Inc. P/E has moved over time to understand its valuation trends.

Biomarin Pharmaceutical Inc. in the last 5 years

  • Overview

  • Trends

Lowest (14.58x)

June 30, 2025

Industry (17.77x)

March 16, 2026

Today (32.51x)

March 16, 2026

Highest (181.43x)

June 30, 2023

LowHigh

Today’s Price to Earnings Ratio: 32.51x

Biomarin Pharmaceutical Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Biomarin Pharmaceutical Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Biomarin Pharmaceutical Inc. image
Biomarin Pharmaceutical Inc.
BUY$11.3B-24.22%32.5110.83%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.6B117.98%135.098.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$119.2B114.32%30.6832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$32.8BNA1155.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$78.8B54.67%17.9931.41%

Stock Returns calculator for Biomarin Pharmaceutical Inc. Stock including INR - Dollar returns

The Biomarin Pharmaceutical Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Biomarin Pharmaceutical Inc. investment value today

Current value as on today

₹89,204

Returns

₹10,796

(-10.8%)

Returns from Biomarin Pharmaceutical Inc. Stock

₹17,296 (-17.3%)

Dollar Returns*

₹6,499 (+6.5%)

Analyst Recommendation on Biomarin Pharmaceutical Inc. Stock

Based on 35 analysts

BUY

74.29%

Buy

25.71%

Hold

0.00%

Sell

Based on 35 analysts, 74.29% of analysts recommend a 'BUY' rating for Biomarin Pharmaceutical Inc.. Average target price of $88.96

Biomarin Pharmaceutical Inc. Share Price Target

Get share price movements and forecasts by analysts on Biomarin Pharmaceutical Inc..

What analysts predicted

35.44%UPSIDE

Target Price

$88.96

Current Price

$57.43

Analyzed by

35 Analysts

Target

$88.96

Biomarin Pharmaceutical Inc. target price $88.96, a slight upside of 35.44% compared to current price of $57.43. According to 35 analysts rating.

Biomarin Pharmaceutical Inc. Stock’s Investor Sentiment and Interest

Search interest for Biomarin Pharmaceutical Inc. Stock has decreased by -45% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-45% versus previous 30 day period

Biomarin Pharmaceutical Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
581
646
648
712
745
747
745
825
776
874
Gross Profit
453
510
523
581
557
611
593
675
636
579
Operating Income
30
14
88
120
113
161
223
276
-46
79
EBITDA
71
51
136
162
156
195
263
319
-5
-3
Interest Expense
3
6
3
3
2
2
2
2
2
2
Depreciation
25
26
27
26
19
23
22
18
18
20
Income Before Tax
41
19
105
132
134
169
238
297
-26
-27
Income Tax Expense
1
-1
16
24
28
44
52
57
4
19
Net Income
40
20
88
107
106
124
185
240
-30
-46
Net Profit Margin
6.95%
3.15%
13.66%
15.05%
14.22%
16.72%
24.92%
29.14%
-3.96%
-5.33%

Biomarin Pharmaceutical Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1,116
1,313
1,491
1,704
1,860
1,846
2,096
2,419
2,853
3,221
Gross Profit
907
1,071
1,175
1,344
1,336
1,375
1,593
1,887
2,273
2,484
Operating Income
-803
-14
-123
-100
-43
-82
160
185
484
533
EBITDA
-698
90
-3
31
83
47
265
306
650
572
Interest Expense
39
42
43
23
29
15
15
17
12
10
Depreciation
-
87
95
105
105
108
101
102
96
79
Income Before Tax
-831
-35
-142
-94
-48
-75
149
188
541
482
Income Tax Expense
-200
81
-65
-70
-903
-11
8
20
114
133
Net Income
-630
-117
-77
-23
854
-64
141
167
426
348
Net Profit Margin
-56.43%
-8.91%
-5.18%
-1.40%
45.90%
-3.47%
6.75%
6.93%
14.96%
10.83%

Biomarin Pharmaceutical Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
20
88
107
106
124
185
426
-30
139
Operating Cash Flow
27
46
118
221
185
174
185
368
99
Investing Cash Flow
-64
-14
90
-16
76
-28
-12
-330
-42
Financing Cash Flow
10
-42
12
-499
2
-38
-4
-2
3
Change in Cash
-30
-8
225
-296
267
105
165
36
61

Biomarin Pharmaceutical Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-117
-77
-23
859
-64
141
167
426
348
Operating Cash Flow
-8
20
48
85
304
175
159
572
827
Investing Cash Flow
-305
264
-31
-53
-366
-20
-111
136
-414
Financing Cash Flow
507
-388
-74
181
0
-18
-18
-526
-42
Change in Cash
189
-104
-56
211
-61
137
30
187
368

Global Institutional Holdings in Biomarin Pharmaceutical Inc.

Funds
Holdings
Dimensional Fund Advisors, Inc.
1.73%
Assenagon Asset Management SA
0.74%
Vestal Point Capital LP
1.56%
Charles Schwab Investment Management Inc
0.74%
Renaissance Technologies Corp
0.94%
See all

Biomarin Pharmaceutical Inc. News & Key Events

  • img

    Today's Timeline - 24 February

    Tue, 10:05 PM

    -

    BioMarin reports Q4 2025 adjusted EPS of 46 cents, beating estimates, but shares drop 2.6% due to Roctavian withdrawal.

    Wed, 01:31 AM

    -

    Analysts provide mixed ratings for BioMarin, with a 12-month price target average of $81.71, reflecting a decline from previous estimates.

Insights on Biomarin Pharmaceutical Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, BMRN stock has moved up by 13.0%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 776.13M → 874.56M (in $), with an average increase of 11.3% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 65.2% return, outperforming this stock by 102.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 29.6% return, outperforming this stock by 45.3%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 240.53M → -46.57M (in $), with an average decrease of 82.1% per quarter

About Biomarin Pharmaceutical Inc.

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
OrganisationBiomarin Pharmaceutical Inc.
Headquarters770 Lindaro Street, San Rafael, CA, United States, 94901
IndustryHealth Technology
CEOMr. Alexander Hardy
E-voting on sharesClick here to vote

Key Management of Biomarin Pharmaceutical Inc.

Name

Title

Mr. Alexander Hardy

President, CEO & Director

Ms. Cristin Hubbard

Executive VP & Chief Commercial Officer

Dr. Gregory Friberg M.D.

Executive VP and Chief Research & Development Officer

Dr. C. Greg Guyer Ph.D.

Executive VP & CTO

Ms. Amy Wireman

Executive VP & Chief People Officer

Mr. Brian R. Mueller CPA

CFO & Executive VP

Mr. George Eric Davis J.D.

Executive VP, Chief Legal Officer & Secretary

Ms. Rashmi Eshwar Ramchandani

VP, Chief Accounting Officer & Principal Accounting Officer

Dr. Kevin Eggan Ph.D.

Chief Scientific Officer & Senior VP of Research and Early Development

Mr. Arpit Dave

Executive Vice President, Chief Digital & Information Officer

FAQs

What is Biomarin Pharmaceutical Inc. share price today?

Biomarin Pharmaceutical Inc. share price today is $57.43 as on at the close of the market. Biomarin Pharmaceutical Inc. share today touched a day high of $58.8 and a low of $56.

What is the 52 week high and 52 week low for Biomarin Pharmaceutical Inc. share?

Biomarin Pharmaceutical Inc. share touched a 52 week high of $73.18 on and a 52 week low of $50.76 on . Biomarin Pharmaceutical Inc. stock price today i.e. is closed at $57.43,which is 21.52% down from its 52 week high and 13.14% up from its 52 week low.

What is Biomarin Pharmaceutical Inc.'s market capitalisation today?

Biomarin Pharmaceutical Inc. market capitalisation is $0.01T as on .

How to invest in Biomarin Pharmaceutical Inc. Stock (BMRN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Biomarin Pharmaceutical Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Biomarin Pharmaceutical Inc. Shares that will get you 0.0261 shares as per Biomarin Pharmaceutical Inc. share price of $57.43 per share as on March 17, 2026 at 1:29 am IST.

What is the minimum amount required to buy Biomarin Pharmaceutical Inc. Stock (BMRN) from India?

Indian investors can start investing in Biomarin Pharmaceutical Inc. (BMRN) shares with as little as ₹92.335 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹923.35 in Biomarin Pharmaceutical Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Biomarin Pharmaceutical Inc. share’s latest price of $57.43 as on March 17, 2026 at 1:29 am IST, you will get 0.1741 shares of Biomarin Pharmaceutical Inc.. Learn more about fractional shares .

What are the returns that Biomarin Pharmaceutical Inc. has given to Indian investors in the last 5 years?

Biomarin Pharmaceutical Inc. stock has given -24.22% share price returns and 27.61% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?